Cargando…

Isolation of broadly neutralizing HIV-1 antibodies from high-throughput single B cell culture

Detalles Bibliográficos
Autores principales:	Longo, NS, Doria-Rose, N, McKee, K, O'Dell, S, Louder, MK, Yang, Z, Bailer, R, Mascola, JR
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3442081/ http://dx.doi.org/10.1186/1742-4690-9-S2-P91

Ejemplares similares

HIV-1 neutralizing antibodies display dual specificity for the primary and coreceptor binding sites and preferential recognition of fully-cleaved Env
por: Li, Y, et al.
Publicado: (2012)

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
por: Huang, Jinghe, et al.
Publicado: (2012)

Removal of variable domain N-linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies
por: Chuang, Gwo-Yu, et al.
Publicado: (2020)

Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability
por: Dubrovskaya, Viktoriya, et al.
Publicado: (2019)

454 pyrosequencing and bioinformatics analysis of the lineage of the broad and potent gp41-directed antibody 10e8
por: Ofek, G, et al.
Publicado: (2012)

Priming with DNA encoding functional trimers and boosting with soluble trimeric protein elicited tier 2 neutralizing antibodies in non-human primates
por: Chakrabarti, BK, et al.
Publicado: (2012)

A short segment in the HIV-1 gp120 V1/V2 region is a major determinant of neutralization resistance to PG9-like antibodies
por: Doria-Rose, NA, et al.
Publicado: (2012)

Structural definition for a new modality of broad and potent antibody neutralization at the CD4-binding site on HIV-1 gp120
por: Zhou, T, et al.
Publicado: (2012)

Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity
por: Steinhardt, James J., et al.
Publicado: (2018)

Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope
por: Schoofs, Till, et al.
Publicado: (2019)

Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting
por: Doria-Rose, Nicole A., et al.
Publicado: (2017)

Characterizing the fitness cost of viral escape from the HIV-1 broadly neutralizing monoclonal antibody VRC01
por: Lynch, RM, et al.
Publicado: (2012)

Protocol to identify and monitor key mutations of broadly neutralizing antibody lineages following sequential immunization of Ig-humanized mice
por: Chen, Xuejun, et al.
Publicado: (2022)

P09-05. Mechanism of HIV-1 resistance to a monoclonal antibody that effectively targets the site of CD4 attachment
por: Wu, X, et al.
Publicado: (2009)

Engineered mice and B cell lines expressing broadly neutralizing antibodies and their unmutated precursors: tools for HIV vaccinology
por: Nemazee, D, et al.
Publicado: (2012)

Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors
por: González, Nuria, et al.
Publicado: (2018)

Improved HIV-1 neutralization breadth and potency of V2-apex antibodies by in silico design
por: Holt, Graham T., et al.
Publicado: (2023)

Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies
por: Cottrell, Christopher A., et al.
Publicado: (2021)

Design clues from functional constraints and broadly neutralizing antibodies
por: Zhou, Tongqing, et al.
Publicado: (2006)

Extended antibody-framework-to-antigen distance observed exclusively with broad HIV-1-neutralizing antibodies recognizing glycan-dense surfaces
por: Lee, Myungjin, et al.
Publicado: (2021)

Characteristics of HIV-1 gp120 molecules that bind ancestor, intermediate and mature forms of VRC01-like antibodies
por: Joyce, M, et al.
Publicado: (2012)

Antibody-directed evolution reveals a mechanism for enhanced neutralization at the HIV-1 fusion peptide site
por: Banach, Bailey B., et al.
Publicado: (2023)

Design of an HIV Env antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes within V1/V2
por: Liao, L, et al.
Publicado: (2012)

Structure-guided modification and optimization of antibody VRC07
por: Kwon, Y, et al.
Publicado: (2012)

Structural definition of a novel CD4-induced epitope that is targeted by a single-headed immunoglobulin to effect broad and potent HIV neutralization
por: Acharya, P, et al.
Publicado: (2012)

Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-120 interface
por: Huang, Jinghe, et al.
Publicado: (2014)

Ontogeny‐based immunogens for the induction of V2‐directed HIV broadly neutralizing antibodies
por: Moore, Penny L., et al.
Publicado: (2017)

Systemic administration of a broadly-neutralizing IgG antibody to generate HIV-neutralization responses in breast milk
por: Fouda, GG, et al.
Publicado: (2012)

Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody
por: Kwon, Young D., et al.
Publicado: (2018)

Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection
por: Wagh, Kshitij, et al.
Publicado: (2016)

A1 The role of virus-antibody co-evolution in the development of a V3-glycan-directed HIV-1 broadly neutralizing antibody lineage
por: Kitchin, D, et al.
Publicado: (2019)

Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models
por: Lacerda, Miguel, et al.
Publicado: (2013)

Structures of HIV-1-Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design
por: Gorman, Jason, et al.
Publicado: (2015)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2012)

Recognition and penetration of the HIV-1 Env glycan shield by potent broadly neutralizing antibodies
por: Julien, J, et al.
Publicado: (2012)

Novel vomputational methods for predicting epitopes of potent and broadly neutralizing HIV-1 antibodies
por: Evans, MC, et al.
Publicado: (2012)

N332-Directed Broadly Neutralizing Antibodies Use Diverse Modes of HIV-1 Recognition: Inferences from Heavy-Light Chain Complementation of Function
por: Pancera, Marie, et al.
Publicado: (2013)

Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain
por: Kwon, Young D., et al.
Publicado: (2023)

P04-07. Guiding the immune system through complex maturation pathways: a novel multi-immunogen approach for elicitation of broadly neutralizing antibodies
por: Xiao, X, et al.
Publicado: (2009)

Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life
por: Zhang, Baoshan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rabti2eoc5hoc68i1sbhtvliuj